

Clark Memorial Health Outpatient COVID Therapy

Complete form and fax to (812) 283-2664 along with a copy of the patient's medication list, ID + insurance card.

****MUST have medication list for order to be honored****

Clark Memorial Pharmacy will fill the prescription and call the patient when it is ready for pickup.

Patient: _____ Date of birth: _____

Address: _____ Best contact number: _____

Allergies: _____ Diagnosis: COVID-19

Treatment: Emergency Use Authorization (non-FDA approved) for treatment of mild to moderate COVID-19 in outpatients **whose symptom onset occurred within the previous 5 days** AND are at high risk of progressing to severe COVID-19 and/or hospitalization. The patient must meet one or more of the criteria below to be considered high risk. Please check:

- Immunocompromised or on immunosuppressive medications
- Unvaccinated or without booster and eligible
- Age \geq 60 years
- Age 18-59
 - Must also have one of the following (Please circle):
 - BMI > 25 kg/m
 - Chronic kidney disease
 - Diabetes
 - Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation [not related to COVID-19])
 - Cardiovascular disease
 - Chronic lung diseases
 - Sickle cell disease
 - Neurodevelopmental disorders
 - Pregnancy

Orders: (therapy will be selected by the pharmacist unless otherwise specified by the ordering provider):

- Preferred: Paxlovid: 300 mg nirmatrelvir with 100 mg ritonavir taken together twice daily for 5 days
- Provider to check if moderate renal impairment (eGFR \geq 30 to < 60 mL/min): Reduce daily dose of nirmatrelvir to 150 mg
- Second line: COVID-19 monoclonal antibody: Sotrovimab 500 mg IV over 30 minutes
 - Vital signs prior to start of infusion, q 15 mins during infusion, then q 30 mins for 1 hour after infusion
 - Diphenhydramine (Benadryl) 50 mg IV x 1 prn mild allergic reaction
 - Famotidine (Pepcid) 20 mg IV x 1 prn mild allergic reaction
 - Epinephrine (Adrenalin) 0.3 mg IM x 1 prn severe anaphylactic reaction AND CALL RAPID RESPONSE TEAM
- Third line: Remdesivir 200mg on day 1 and 100mg on day 2 & 3

Paxlovid exclusion criteria:

- Age < 12 years or weight < 40kg
- Severe renal impairment (eGFR <30mL/min)
- Co-administration with drugs highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions:

Alfuzosin	Ergotamine	Pethidine	Ranolazine
Amiodarone	Flecainide	Pimozide	Sildenafil (Revatio®)*
Clozapine	Lovastatin	Piroxicam	*If used for PAH
Colchicine	Lurasidone	Propafenone	Simvastatin
Dihydroergotamine	Methylergonovine	Propoxyphene	Triazolam
Dronedaron	Midazolam (oral).	Quinidine	

- Co-administration with potent CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance

Apalutamide	Phenobarbital	Rifampin
Carbamazepine	Phenytoin	St. John's Wort

Monoclonal AB exclusion criteria:

- Age < 18
- Hospitalized due to COVID-19
- Require oxygen therapy due to COVID-19
- Require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity
- Weight < 40 kg

Remdesivir exclusion criteria:

- Age < 12 or weight < 40 kg
- Severe renal impairment (eGFR < 30 mL/min)

Provider name (print): _____

Provider signature: _____ Date: _____ Time: _____